Who is sponsoring NCT02728726?

NCT02728726 is sponsored by Mayo Clinic.

What condition does NCT02728726 study?

NCT02728726 studies General Surgery.

What drugs are being tested in NCT02728726?

Interventions: Sugammadex, Placebo.

What is the status of NCT02728726?

NCT02728726 is currently COMPLETED.

Last reviewed 2022-06-21 · How we verify

Randomized Double---Blinded, Controlled Trial to Compare the Effectiveness of Sugammadex vs. Placebo to Prevent Residual Neuromuscular Block in the Post---Anesthesia Care Unit as Evaluated With a Non---Invasive Respiratory Volume Monitor

NCT02728726 Phase 4 COMPLETED Results posted

The study is designed to determine whether patients who receive sugammadex immediately after tracheal extubation will exhibit a decrease in the incidence of postoperative residual paralysis and an associated decrease in the incidence of postoperative respiratory depression.

Details

Lead sponsor	Mayo Clinic
Phase	Phase 4
Status	COMPLETED
Enrolment	260
Start date	2016-06
Completion	2019-12

Conditions

General Surgery

Interventions

Sugammadex
Placebo

Primary outcomes

Decreased Minute Ventilation (MV) — 15---30 minutes after Post-anesthesia care unit (PACU) arrival
The number of subjects who have a MV as defined as \[MV \<80% MV predicted (MVPRED) based on Body Surface Area\]. MV (or respiratory minute volume or minute volume) is the volume of gas inhaled (inhaled minute volume) or exhaled (exhaled minute volume) from a person's lungs per minute.
Decreased Average Minute Ventilation (MV) — 15---30 minutes after Post-anesthesia care unit (PACU) arrival
The number of subjects who have an average MV \<80% MV predicted (MVPRED) based on Body Surface Area. MV (or respiratory minute volume or minute volume) is the volume of gas inhaled (inhaled minute volume) or exhaled (exhaled minute volume) from a person's lungs per minute.

Countries

United States